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Abstract
We hypothesized that a common SNP in the 3’ untranslated region of the upstream transcription factor 1 (USF1), rs3737787,
may affect lipid traits by influencing gene expression levels, and we investigated this possibility utilizing the Mexican
population, which has a high predisposition to dyslipidemia. We first associated rs3737787 genotypes in Mexican Familial
Combined Hyperlipidemia (FCHL) case/control fat biopsies, with global expression patterns. To identify sets of co-expressed
genes co-regulated by similar factors such as transcription factors, genetic variants, or environmental effects, we utilized
weighted gene co-expression network analysis (WGCNA). Through WGCNA in the Mexican FCHL fat biopsies we identified
two significant Triglyceride (TG)-associated co-expression modules. One of these modules was also associated with FCHL,
the other FCHL component traits, and rs3737787 genotypes. This USF1-regulated FCHL-associated (URFA) module was
enriched for genes involved in lipid metabolic processes. Using systems genetics procedures we identified 18 causal
candidate genes in the URFA module. The FCHL causal candidate gene fatty acid desaturase 3 (FADS3) was associated with
TGs in a recent Caucasian genome-wide significant association study and we replicated this association in Mexican FCHL
families. Based on a USF1-regulated FCHL-associated co-expression module and SNP rs3737787, we identify a set of causal
candidate genes for FCHL-related traits. We then provide evidence from two independent datasets supporting FADS3 as a
causal gene for FCHL and elevated TGs in Mexicans.
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Introduction
Familial combined hyperlipidemia (FCHL) is a common
atherogenic dyslipidemia conferring nearly two-fold greater risk
for coronary heart disease [1]. FCHL is characterized by familial
segregation of elevated fasting plasma triglycerides (TGs), total
cholesterol (TC), or both [2,3]. Another common characteristic of
FCHL is elevated levels of fasting plasma apolipoprotein B (ApoB)
[1]. In Mexico 12.6% of the general population have combined
hyperlipidemia, suggesting that FCHL is a common dyslipidemia
in the Mexican population [4].
We previously identified an association within the region of
chromosome 1q21-q23 consistently linked to FCHL [5–9] with the
associated linkage disequilibrium (LD) bin containing variants in
upstream transcription factor 1 (USF1), and the adjacent gene, F11
receptor (F11R) [10]. The association with this LD bin containing
USF1 has been replicated for FCHL, and its component traits TC,
TGs and low density lipoprotein cholesterol (LDL-C) in different
populations [11–13], including Mexicans [14]. It has become
evident that the SNP rs3737787 residing in the 39 UTR of USF1
captures the disease-associated signal, although its relationship to
the causal polymorphism contributing to the etiology of FCHL is
unknown. Previous studies involving direct sequencing, extensive
genotyping and gene expression analyses of the USF1 region have
not identified any SNPs in the rs3737787 LD bin altering the
coding sequence or the expression of USF1 itself in fat [10] or
lymphoblasts [11]. It has, however, been demonstrated that genes
known to be regulated by USF1 were differentially expressed
between rs3737787 genotype groups in Finnish fat biopsies [15].
The direct targets of USF1 were previously identified using
chromatin immunoprecipitation and high-resolution promoter
microarrays (ChIP-Chip) [16]. Indirect USF1 target genes remain
unknown.
We hypothesized that rs3737787 affects the function of USF1,
and that this effect could be identified as the differential expression
of genes directly or indirectly regulated by USF1. To test this
hypothesis we first identified the direct and indirect targets of
USF1 by transiently over-expressing USF1 in vitro and assaying for
differential expression using gene expression microarrays. Next we
showed that there is overlap between the genes regulated by USF1
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FCHL case/control fat biopsies. Adipose tissue is the major
storage depot for TGs in the body, and has been suggested to play
an important role in the hypertriglyceridemia component of
FCHL [17–19]. It is also worth noting that TGs are the major
focus of our study because the most associated FCHL-component
trait with USF1 has been TGs [10,14,20]. Liver would also be a
highly relevant tissue for gene expression studies of dyslipidemia
due to its key role in the regulation of lipid metabolism. However,
adipose tissue biopsies represent significantly less severe compli-
cations to the research subjects than liver biopsies. Adipose tissue
has thus become the most studied tissue in FCHL because of its
relevance to TG metabolism and the relatively minimal invasive-
ness of collecting subcutaneous fat biopsies [10,15,18,21–26].
Recent systems genetic strategies that characterize interactions
between genotype data and co-expression modules have success-
fully been applied to complex diseases [27–31]. Here we integrate
weighted gene co-expression network analysis (WGCNA) with the
SNP rs3737787 genotypes to identify an FCHL-related module
and develop a systems genetic gene-screening strategy for causal
candidate genes of FCHL related traits. We were able to identify
two TG related co-expression modules, which are clusters of genes
likely to be co-regulated by similar factors (i.e. transcription
factors, genetic variants, or environmental effects). We tested the
co-expression modules for association with FCHL, FCHL
component traits, and rs3737787 genotypes. Several authors have
suggested that genetic markers can be used as causal anchors for
dissecting the causal relationships between traits. Since random-
ization is the most convincing method for establishing causal
relationships between two correlated traits, it is natural to make
use of genetically randomized genotypes (implied by Mendel’s
laws) to derive causality tests that are less susceptible to
confounding by hidden variables [32–37]. Here we utilized the
network edge orienting (NEO) software [37] coupled with the SNP
rs3737787 genotypes to screen for causal candidate genes of
FCHL and FCHL component traits. We followed-up a causal
candidate gene for both FCHL and TGs, fatty acid desaturase 3
(FADS3), residing in the FADS1-2-3 locus, which was recently
implicated for TGs in a meta-analysis of genome-wide association
studies for lipids in Caucasians [38]. In an independent Mexican
FCHL dataset we replicate the association for TGs with the
previously associated genome-wide SNP. To summarize, we
identify two co-expression modules associated with TGs, the key
component trait of FCHL. We then demonstrate that one of these
co-expression modules is also associated with the SNP rs3737787.
Our genetic marker based causal screening analysis implicates 18
FCHL causal candidate genes inside this module. Multiple lines of
evidence validate the role of FADS3 as a causal candidate gene for
FCHL.
Results
Relating rs3737787 Correlated Gene Expression to USF1
We hypothesized that if the SNP rs3737787 tagged LD bin
alters the function of the transcription factor USF1, the effect could
be assayed on the downstream expression of USF1 target genes, or
the subsequent targets of those genes. We transiently over-
expressed USF1 in the HEK293T cell line and assayed for
differential expression using gene expression microarrays to detect
both direct and indirect targets of USF1. Over-expression of USF1
was validated by western blot (Figure S1). In our over-expression
analysis, we identified 2,897 genes that were directly or indirectly
regulated by USF1 over-expression in vitro (Table S1). We validated
the differential expression of nine genes (AGT, AK5, CNR1, GALR2,
IGFBP7, KISSR1, PLXDC1, PLXNC1 and PROK2) using quantita-
tive real-time PCR (Figure S2).
Next we utilized an independent gene expression dataset of 70
Mexican FCHL case/control fat biopsies whose clinical charac-
teristics are given in Table 1. We observed 972 genes (gene
expression profiles) significantly correlated with rs3737787 geno-
types using an additive model (Table S2). The rs3737787
correlated genes had significant overlap both with i) the set of
USF1 regulated genes identified in our USF1 over-expression
experiment (n=277; p-value=3.0610
25; fold-enrichment=1.22)
and ii) the previously published genes identified by ChIP-Chip
[16] which are directly regulated by USF1 (n=117; p-value=
0.0051; fold-enrichment=1.23). Furthermore, we also observed
significant overlap between the rs3737787 correlated genes and the
2,189 genes differentially expressed between FCHL cases and
normolipidemic controls (n=245; p-value=0.0030; fold-enrich-
ment=1.16) (Table S3), supporting a link from rs3737787 to FCHL
etiology. Taken together, the overlap between rs3737787 correlated
genes and genes regulated by USF1 suggest that the effect of
rs3737787 on FCHL is mediated through the transcription factor
USF1.
Weighted Gene Co-Expression Network Analysis
The gene expression variation between individuals in the
Mexican FCHL fat biopsies is due to a combination of genetic and
Table 1. Clinical characteristics for Mexican FCHL fat biopsy
cases/controls.
Clinical Trait FCHL Normolipidemic P-value
A
n (Male) 38 (21) 32 (15)
Age 3869.3 3868.7 0.91
BMI 2762.4 2562.9 0.02
Total Cholesterol (mmol/L) 6.861.2 4.660.74 2.7610
213
Triglycerides (mmol/L) 4.762.6 1.761.1 9.3610
28
ApoB (g/L) 140622 92623 2.9610
212
AStudent’s t-test p-value.
doi:10.1371/journal.pgen.1000642.t001
Author Summary
By integrating a genetic polymorphism with genome-wide
gene expression levels, we were able to attribute function
to a genetic polymorphism in the USF1 gene. The USF1
gene has previously been associated with a common
dyslipidemia, FCHL. FCHL is characterized by elevated
levels of total cholesterol, triglycerides, or both. We
demonstrate that this genetic polymorphism in USF1
contributes to FCHL disease risk by modulating the
expression of a group of genes functionally related to
lipid metabolism, and that this modulation is mediated by
USF1. One of the genes whose expression is modulated by
USF1 is FADS3, which was also implicated in a recent
genome-wide association study for lipid traits. We
demonstrated that a genetic polymorphism from the
FADS3 region, which was associated with triglycerides in a
GWAS study of Caucasians, was also associated with
triglycerides in Mexican FCHL families. Our analysis
provides novel insight into the gene expression profile
contributing to FCHL disease risk, and identifies FADS3 as a
new gene for FCHL in Mexicans.
Systems Genetics of FCHL
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the cases with factors leading to hyperlipidemia, and contrasting
the cases with the controls will allow these factors to be more easily
identified. We utilized weighted gene co-expression networking
analysis (WGCNA) to identify gene co-expression modules
summarizing the main trends in variation for the Mexican FCHL
case/control fat biopsies. The WGCNA method clustered the
14,942 gene expression probes on the Mexican FCHL case/
control microarrays into 28 gene co-expression modules (Table
S4). Each of the modules was labeled with a unique color as an
identifier. We then characterized each module for enrichment of
functionally-related genes (Table S5). To summarize the gene
expression profiles of the highly correlated genes inside a given
module, we use the first principal component, which is referred to
as the module eigengene (ME). We tested the amount of trait
variance explained by each ME (Table S6), which provides insight
into how much influence each module has on a particular trait.
We also tested each ME for correlation with the quantitative
FCHL component traits: TC, TG and ApoB (Figure 1). Given the
high level of correlation between the FCHL component traits
(correlation TC & TG=0.57; correlation TC & ApoB=0.90;
correlation TG & ApoB=0.59), we approximate the total number
of independent tests to be 2. Therefore, a Bonferroni correction
would have to account for a total of 56 multiple comparisons (28
modules62 independent tests). Thus using Bonferroni correction
we would require a p-value less than or equal to 8.9610
24 in
order to maintain an experiment-wide type I error rate of 0.05.
This highlights a major statistical advantage of our module based
analyses over conventional differential expression analyses which
have to account for tens of thousands of multiple comparisons.
TG-Associated Module Eigengenes
We observed two modules (or more precisely MEs) significantly
associated with TGs (tan ME correlation=0.43, p-value=2610
24,
Bonferroni-corrected p-value=0.011; midnightblue ME correla-
tion=0.52, p-value=5610
26, Bonferroni-corrected p-value=
0.00028), the key component trait of FCHL. Interestingly, the
associations of the tan and midnightblue ME with TGs were
experiment-wide significant as they were less than the most
conservative multiple comparison correction (Bonferroni-corrected
p-value for 56 tests, p-value#8.9610
24). Using a multivariate
regression model, we observed that the two TG associated MEs
explained 30% of TG trait variance, which is relatively high
considering this is a complex trait. Both the tan and midnightblue
MEs were also marginally associated with qualitative FCHL disease
status (tan ME correlation=0.33, p-value=0.006; midnightblue ME
correlation=0.36, p-value=0.002), although these associations did
not beatmultiple testingcorrection (Figure 1).Theassociationpattern
Figure 1. Correlation of module eigengenes (ME) with clinical traits and rs3737787 SNP genotypes. The rows are labeled by the ME
color, and in parentheses is the number of genes in the module. The columns are labeled by SNP or clinical trait. The quantitative clinical traits, all
except for FCHL which is qualitative, were corrected for significant covariates (age and/or sex) and standardized before use in analyses. The
correlation coefficients are shown for each cell, and in parentheses is the p-value for the significance of the correlation. Cells are colorized basedo n
the strength and sign of the correlation according to the scale on the right hand side of the figure.
AThe tan module has been renamed to the USF1-
regulated FCHL-associated (URFA) module.
doi:10.1371/journal.pgen.1000642.g001
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FCHL: elevated plasma levels of TC, TG and ApoB (TC
correlation=0.28, p-value=0.02; TG correlation=0.43, p-val-
ue=2610
24; ApoB correlation=0.32, p-value=0.009) (Figure 1).
The midnightblue ME had a similar association pattern with the
FCHL component traits (TG correlation=0.52, p-value=5610
26;
ApoB correlation=0.31, p-value=0.01), although it was not
associated with TC (correlation=0.17, p-value=0.20) (Figure 1).
We observed significant overlap (p-value#2.7610
210) between the
FCHL differentially expressed genes and the tan and midnightblue
module genes (tan module overlap p-value=2.7610
210;m i d n i g h t -
blue module overlap p-value=4.6610
231) (Table 2). Given that
FCHL is known to be a complex disease, it is not surprising that
FCHL status is associated with multiple modules. Both of these
modules are likely to be regulated by different genetic or
environmental factors which contribute to the etiology of FCHL.
rs3737787-Associated Module Eigengenes
Integrating the co-expression modules with genetic data
provides insight into the function and regulation of each module.
The turquoise and tan MEs were associated with the rs3737787
genotypes (turquoise ME correlation=0.28, p-value=0.02; tan
ME correlation=0.33, p-value=0.006) (Figure 1). We observed a
significant overlap between the rs3737787 correlated genes and
both the turquoise and tan module genes (Table 3). The tan
module was the only module to be associated with FCHL, the
FCHL component trait signature, and rs3737787 genotypes. To
emphasize the biological implications of the tan module, we
renamed it as the USF1-regulated FCHL-associated (URFA)
module. The turquoise module was not significantly associated
with FCHL, suggesting that while the expression of turquoise
module genes depends on rs3737787 genotypes, the gene functions
of the turquoise module are less likely to be related to FCHL
(Figure 1, Table S5). These results demonstrate that rs3737787
genotypes predict the expression of many genes, some of which
predispose to FCHL.
We should point out that our sample size of 70 individuals
provides 80% power to detect a significant association (p-
value#0.05) with correlation coefficient=0.33, and only limited
power to rule out associations with a correlation coefficient,0.33.
To have 80% power to detect a significant association (p-
value#0.05) when the true correlation coefficient=0.2 requires
194 individuals, and when the true correlation coefficient=0.1
requires 783 individuals. Therefore our sample size does not
permit us to rule out associations of smaller magnitude (correlation
coefficient,0.33). However, our sample size of 70 individuals
provides enough power to detect significant moderate correlations
(correlation coefficient$0.33) between eigengenes, SNPs, and
clinical traits.
USF1-Regulated FCHL-Associated (URFA) Module
Characterization
The URFA module contains 504 co-expressed genes that are
enriched for the gene ontology (GO) Biological Process categories
of Cellular Lipid Metabolic Processes and Lipid Metabolic
Processes (p-values=1.0610
25 and 9.3610
26; Benjamini-Hoch-
berg multiple comparison corrected p-values=0.022 and 0.039)
(Table S5). The URFA ME accounts for 10% of the variation of
FCHL, 6% of TC, 17% of TG, and 9% of ApoB (Table S6). The
fact that the URFA ME was associated with rs3737787 reflects the
fact that most module genes are at least partially regulated by this
SNP. To evaluate whether the module causally affects FCHL
component traits, we utilized the Network Edge Orienting (NEO)
R software package [37] which takes SNP genotypes as input into
structural equation models that compute causal edge orienting
scores (referred to as LEO.NB scores). Since we are only
considering a single SNP (rs3737787) we computed LEO.NB.Sin-
gleMarker scores for the causal orientation of a MERtrait. The
LEO.NB.SingleMarker score is a relative model fitting index for the
causal model (rs3737787RMERtrait) relative to alternative
causal models, and the larger the value for the LEO.NB.Single-
Marker score the stronger the evidence that this causal orientation
is correct. We required that the our causal model fit at least two
times better than the next best alternative model, which equates to
a LEO.NB.SingleMarker score of 0.3 [28] (please see the Materials
and Methods for a detailed description). We found sufficient
evidence to infer a causal relationship between the URFA ME and
fasting plasma TGs levels (LEO.NB.SingleMarker score=0.31), the
key component trait of FCHL. The LEO.NB.SingleMarker score for
the URFA ME to FCHL was 0.25. We then used the NEO
software to prioritize genes inside the URFA module by
calculating the LEO.NB.SingleMarker scores evaluating the causal
model (rs3737787Rgene expressionRtrait). We identified 18
causal candidate genes for FCHL, and 171 causal candidate
genes for fasting plasma TGs levels (Table S7). We observed 13
causal candidate genes for both FCHL and TG. None of the
URFA module genes showed evidence for causally affecting TC or
ApoB. Since our interest was in FCHL disease status, we
characterized the 18 causal candidate genes for FCHL disease
status as potential candidate genes for genetic association studies in
Mexican FCHL families (Table 4).
Replication of Association to the FADS1-2-3 Gene Locus
Fatty acid desaturase 3 (FADS3) was 1 of the 18 genes causally
linked to FCHL. Interestingly, variation from the FADS1-2-3
Table 2. Overlap of FCHL modules with FCHL differentially
expressed gene list.
Module
FCHL Differentially Expressed Genes
(n=2,189)
Overlap (Enrichment
A)P - v a l u e
Tan (URFA
B) (n=504) 142 (1.60) 2.7610
210
Midnightblue (n=282) 130 (2.55) 4.6610
231
AEnrichment is calculated as the fold-change in enrichment defined as the
observed overlap divided by the expected overlap.
BThe tan module has been renamed to the USF1-regulated FCHL-associated
(URFA) module.
doi:10.1371/journal.pgen.1000642.t002
Table 3. Overlap of rs3737787 modules with genes
differentially expressed by the rs3737787 genotypes.
Module rs3737787 Correlated Genes (n=972)
Overlap (Enrichment
A) P-value
Turquoise (n=1609) 345 (2.72) 1.6610
282
Tan (URFA
B) (n=504) 188 (4.70) 1.4610
287
AEnrichment is calculated as the fold-change in enrichment defined as the
observed overlap divided by the expected overlap.
BThe tan module has been renamed to the USF1-regulated FCHL-associated
(URFA) module.
doi:10.1371/journal.pgen.1000642.t003
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meta-analysis of GWAS in Caucasians [38]. We chose to follow-up
the SNP rs174547 residing in the FADS1-2-3 locus which was
significantly associated with TGs at the genome-wide level in this
previous meta-analysis [38]. The same study demonstrated that the
SNP rs102275, in complete LD with rs174547 in Caucasians,
predicted the expression of FADS1 and to a lesser extent FADS3 in
human liver [38]. We hypothesized that because FADS3 expression
was associated with FCHL, any variation affecting the expression of
FADS3 could be associated with FCHL or an FCHL component
trait, especially TGs. Therefore we genotyped both rs174547 and
rs102275 in the Mexican FCHL case/control fat biopsies (n=70).
We observed a large allele frequency discrepancy between the
Mexican and Caucasian populations for both rs174547 and
rs102275, which was also present in the HapMap Phase 3 data
(rs174547: Caucasian T allele=0.66, Mexican T allele=0.34;
rs102275: Caucasian T allele=0.65, Mexican T allele=0.30). The
LD between rs174547 and rs102275 was reduced in the Mexican
samples compared to the Caucasian population (Mexican r
2=0.90;
Caucasian r
2=1.0), indicating that the SNPs are no longer
completely redundant in the Mexican population. Therefore, we
report the results for both SNPs (Table 5). In the 70 Mexican
individuals undergoing fat biopsies, the major alleles of both SNPs
were associated with hypertriglyceridemia as defined by TGs
dichotomized by the 90
th age-sex specific population percentiles
(rs174547 p-value=0.024, rs102275 p-value=0.012). Despite the
switch in allele frequencies, the association was observed with the
same allele (C) as in Caucasians and thus, the direction of the
association is identical to the previous genome-wide association
study[38]. Wethen proceeded to test thesetwo SNPsfor replication
in the Mexican families with FCHL and its component traits
(Table 6). The major alleles of both SNPs were associated with
hypertriglyceridemia as defined by TGs dichotomized by the 90
th
age-sex specific population percentiles (rs174547 p-value=0.0071,
rs102275 p-value=0.0034), and again the direction of the
association was consistent with the previous genome-wide associa-
tion study [38]. The association in the Mexican FCHL families with
rs102275 was Bonferroni corrected significant (rs102275 corrected
p-value=0.034). These results replicate the findings for the FADS1-
2-3 locus in the Mexican population.
Predicting the Expression of FADS1 and FADS3 in Adipose
Tissue
Of the three fatty acid desaturase genes in the FADS1-2-3 locus,
we observed that only the expression of FADS3 was associated with
FCHLdiseasestatusinadiposetissue (204257_atcorrelation=0.31,
p-value=0.0084; 216080_s_at correlation=0.31, p-value=0.0092).
This result indicates that increasing expression of FADS3 is associated
with increased risk for FCHL. We then tested whether the two SNPs
rs174547 and rs102275 predicted the expression of FADS1 and/or
FADS3 in the Mexican FCHL case/control fat biopsies. We observed
a marginally significant prediction of FADS1 expression (rs174547
correlation=0.26, p-value=0.027; rs107225 correlation=0.20, p-
value=0.089), and little to no evidence for prediction of FADS3
Table 4. Genes causally linked to FCHL (rs3737787RGene ExpressionRFCHL) with LEO.NB.SingleMarker score$0.30 from the
URFA module.
Affymetrix ProbeSet Gene Name Associations Network Connectivity Kathiresan GWAS Minimum Regional P-values
B
LDL TG
214033_at ABCC6 CAD, HDL, PSE, TG 34.1 7.5610
23 (rs212077) 1.2610
24 (rs9924674)
203925_at GCLM AvgIMT, CHD, MI, T2D, VCI 33.1 8.4610
24 (rs2281525) 4.1610
23 (rs12070273)
209740_s_at PNPLA4 NA 28.3 NA
C NA
C
204257_at FADS3 HDL, PUFA, TG 27 4.2610
24 (rs174549) 3.3610
27 (rs102275)
227117_at XPOT NA 20.3 1.2610
23 (rs10878151) 1.1610
23 (rs11504159)
212799_at STX6 NA
A 17.2 1.5610
23 (rs17299701) 9.1610
23 (rs6658713)
204057_at IRF8 HEPC 15.3 2.6610
24 (rs903194) 5.7610
24 (rs4843966)
214152_at CPR8 NA 12.9 7.9610
23 (rs12902248) 1.6610
22 (rs4774780)
214696_at C17orf91 NA 12.1 7.9610
25 (rs17761734) 6.6610
24 (rs2955626)
205404_at HSD11B1 BC, HT, T2D 11.1 1.6610
24 (rs6659502) 2.1610
23 (rs7536585)
236664_at AKT2 MetS, T2D, TC/HDL 9.8 7.0610
23 (rs10412191) 4.6610
24 (rs4803342)
203625_x_at SKP2 NA 8.9 9.7610
23 (rs1610218) 4.8610
24 (rs6895261)
50374_at C17orf90 NA 8.5 2.5610
23 (rs11150780) 1.8610
22 (rs7210742)
229144_at KIAA1026 NA 5.3 9.3610
24 (rs9442193) 3.5610
23 (rs12141589)
205452_at PIGB NA 3.6 7.9610
23 (rs12902248) 1.6610
22 (rs4774780)
209268_at VPS45A NA
A 2.7 5.1610
23 (rs7537292) 1.3610
22 (rs6587552)
214252_s_at CLN5 NCL 2.2 3.5610
23 (rs851251) 9.5610
23 (rs1537063)
228641_at CARD8 AZ, RA 0.8 4.9610
25 (rs3760802) 1.6610
24 (rs11669775)
AvgIMT indicates average intima-media thickness; AZ, Alzheimer’s disease; BC, body composition; CAD, coronary artery disease; CHD, coronary heart disease; HDL, low
levels of high-density lipoprotein cholesterol; HEPC, hepatitis-C; HT, hypertension; MI, myocardial infarction; NCL, neuronal ceroid-lipofuscinosis; PSE, pseudoxanthoma
elasticum; PUFA, polyunsaturated fatty acids; T2D, type II diabetes; TC/HDL, total cholesterol/high-density lipoprotein cholesterol ratio; TG, hypertriglyceridemia; and
VCI, vascular cognitive impairment.
ASTX6 and VSP45A proteins are known to physically interact.
BMinimum P-value from a region spanning 1 Mbp on either side of the gene from Kathiresan et al., 2009 [38].
CPNPLA4 resides on the X chromosome, and there weren’t any SNPs tested within the specified region in the Kathiresan et al., 2009 [38].
doi:10.1371/journal.pgen.1000642.t004
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correlation=20.14, p-value=0.25). These results were consistent
with the results from Caucasian human liver samples where rs102275
predicted the expression of FADS1 and to a lesser extent FADS3
expression.
Discussion
By integrating both genetic and transcriptome profile data we
were able to attribute a function to the FCHL associated,
rs3737787-tagged LD bin. We first provide evidence that the
SNP rs3737787 has an effect on global expression profiles, and
further evidence suggesting that this effect is mediated by USF1.
We then identified two TG-associated co-expression modules one
of which (the URFA module) was also associated with the FCHL,
the other FCHL component traits, and rs3737787 genotypes. The
URFA module was enriched for the GO Biological Process
categories Lipid Metabolic Process and Cellular Lipid Metabolic
process. The URFA module also contained eighteen genes
causally linked to FCHL. One of the causal genes for FCHL,
FADS3, coincides with a previous genome-wide significant
association signal for TGs [38]. We demonstrate that the
genome-wide associated SNP also has an effect on TGs in the
Mexican FCHL families. In summary, we demonstrate the
function of the rs3737787 LD bin, construct and characterize a
co-expression network for Mexican FCHL case/control fat
biopsies, and demonstrate that the loci identified as causal can
harbor variants associated with FCHL or FCHL component traits.
There arethreeSNPs from the rs3737787tagged LDbinresiding
within the USF1 gene. Although our currentstudy does not allow us
to pinpoint which of these three USF1 SNPs in LD is the actual
causative SNP, we were able to demonstrate that an allele-
dependent effect of the rs3737787 tagged LD bin on downstream
genes is mediated by USF1 and not the adjacent gene F11R. To
identify the causal SNP in USF1, additional functional studies are
warranted that investigate allele-dependent effects of each of the
three SNPs on USF1 isoform and protein levels.
Gene co-expression networking methods have been successfully
applied in a variety of different settings [39–46]. We utilized
weighted gene co-expression network analysis (WGCNA) for the
following reasons. First, it is assumed that co-expression is a
biological process, and as such a co-expression module is a set of
genes that are likely to be co-regulated by similar factors (e.g. shared
transcription factors, genetic variants or environmental effects).
Second, modules (and corresponding module eigengenes) represent
a biologically motivated data reduction method which greatly
alleviates the multiple comparison problem inherent in genomic
data analysis. Third, we provide annotation tables for module
membership (Table S4) and URFA module causal candidate genes
measures (Table S7), which provides a resource for other
investigators. Our unbiased module detection analysis identified a
module that was associated with rs3737787 genotypes, fasting
plasma TG levels, FCHL disease status, and contained genes that
arecausaldrivers of TG levels. It is difficult toascertainif the URFA
module can be identified in other tissues. Nevertheless, we consider
that the identification of the URFA module in fat does further
implicatea biological role offattissue inFCHL, althoughwe cannot
establish whether these FCHL modules are tissue-specific.
Our approach provides insight to how the SNP rs3737787 confers
increased risk for FCHL, by demonstrating that it regulates the URFA
module eigengene which in turn contributes to increased TG levels, a
key component trait of FCHL. The URFA module can be considered
rs3737787-genotype dependent, while the other TG associated
midnightblue module was not dependent on rs3737787 genotypes.
The variation regulating other modules remains to be discovered.
We conducted a literature search for links between the 18 FCHL
causal candidate genes from the URFA module to lipid related
phenotypes and/or atherogenic processes. Three of the FCHL causal
candidate genes were directly related to lipid phenotypes (ABCC6,
AKT2, HSD11B1), and two others were likely to be related to lipid
phenotypes (FADS3, PNPLA4) via homology. We also identified genes
which were related to atherogenic processes such as inflammation
(CARD8, ICSBP1, STX6) and reactive oxygen species (GCLM). Among
the 18 genes there are also putative genes and genes with little known
Table 5. Replication of association evidence for FADS1-2-3 locus in 70 Mexican FCHL case/control fat biopsies with qualitative lipid
traits.
SNP Minor Allele MAF FCHL FCHL Component Traits
TC TG ApoB
Beta P-value Beta P-value Beta P-value Beta P-value
rs174547 T 0.33 20.5960.35 0.09 20.4260.35 0.23 20.9460.42 0.024 20.7560.37 0.044
rs102275 T 0.29 20.6260.35 0.072 20.560.35 0.16 21.1260.45 0.012 20.7460.37 0.044
doi:10.1371/journal.pgen.1000642.t005
Table 6. Replication of association evidence for FADS1-2-3 locus in Mexican FCHL families with qualitative lipid traits.
SNP Minor Allele MAF FCHL FCHL-Related Traits
TC TG ApoB
Z P-value Z P-value Z P-value Z P-value
rs174547 T 0.28 20.55 0.58 20.37 0.7 22.69 0.0071 20.29 0.77
rs102275 T 0.23 20.65 0.52 21.08 0.28 22.93 0.0034
A 20.91 0.36
AMultiple testing corrected significant (Bonferroni correction#0.0063=0.05/[2 SNPs64 traits]).
doi:10.1371/journal.pgen.1000642.t006
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vivo or in vitro, and will be useful in understanding how the URFA
module contributes to the etiology of FCHL. Importantly, some of the
genes causally linked to FCHL (ABCC6, AKT2, FADS3, GCLM,
HSD11B1) have already been associated with FCHL related traits in
humans (Table 3 and Table S8). Studies in mice have also
demonstrated that genetic manipulation of Abcc6, Akt2 and Hsd11b1
affect FCHL component traits or related phenotypes [47–49].
Together these data support a causal association between the 18
causal candidate genes from the URFA module and FCHL. Although
we present strong statistical and biological evidence in support of our
findings, we want to emphasize that additional biological validation
studies are warranted.
Identifying the associated gene(s) from the genetic association
evidence for the FADS1-2-3 locus in humans is complicated by the
fact that multiple LD blocks have been associated with several
different but related lipid traits [38,50–57], as well as coronary
artery disease [55] and nonfatal myocardial infarction [57]. It has
been established that both FADS1 and FADS2 function as a fatty
acid desaturase [58,59] in the pathway generating polyunsaturated
fatty acids from the essential Omega-3 and Omega-6 fatty acids.
The function of FADS3 is unknown, although it shares 52%
sequence identity with FADS1 and 62% with FADS2 [60],
suggesting that FADS3 may also function as a fatty acid desaturase.
Our findings demonstrate that FADS3 expression is regulated by
rs3737787 genotypes in adipose tissue, and that this differential
expression causes increased risk for FCHL. Neither FADS1 nor
FADS2 were regulated by rs3737787 genotypes, nor were the
expression of these two genes associated with FCHL. Future
studies to identify the function of FADS3 will be required to
elucidate the mechanisms by which differential regulation of
FADS3 in adipose tissue predisposes to FCHL.
Our systems genetic analysis integrated SNP genotypes with
gene expression levels to unravel the complex disorder that is
familial combined hyperlipidemia. With this study we have
identified new intriguing causal candidate genes for genetic studies
with FCHL, and we provide causal candidate genes for FCHL
related component traits (Table S7). These data may form the
starting point for future studies that further elucidate the etiology
of FCHL. The fact that we were able to account for 30% of fasting
plasma TG trait variance is very promising, and that it required
the expression of hundreds of genes to observe this demonstrates
that FCHL is a complex and heterogeneous disorder. The URFA
module is regulated by the SNP rs3737787 in USF1, suggesting
that variation in the USF1 gene acts as a master regulator of genes
contributing to the FCHL phenotype. Our analysis of gene
expression and SNP genotype data from few but carefully selected
individuals demonstrates that a well designed systems genetic study
can lead to insights on complex disease traits.
Materials and Methods
USF1 Over-Expression
Transient transfection and over-expression of USF1 were
conducted in HEK293T cells, which express the USF1 protein
(Figure S1). The USF1 coding region was PCR amplified from
cDNA (forward-primer=ATGAAGGGGCAGCAGAAAACAG,
reverse primer=TTAGTTGCTGTCATTCTTGATG) and
cloned into pcDNA4/HisMax TOPO TA mammalian expression
vector (Invitrogen, Cat. No. K864-20). Plasmid for transient
transfection was prepared using the Endo Free Plasmid Kit Mega
(Qiagen, Cat. No. 12363). Over-expression of USF1 was validated
by western blot using Anti-HisG-HRP (Invitrogen, Cat No. R941-
25) and Rabbit Anti-USF1 (Santa-Cruz, Cat. No. sc-8983) (Figure
S1). Total RNA was collected using the RNeasy Plus Mini Kit (Cat
No. 74134) 48 hours after transient transfection of HEK293T
cells. Microarray hybridization has been described previously [22].
After applying the quality control pipeline, a total of 16,570
probesets passed and were utilized in the analyses. Differential
expression between USF1 and empty vector control transfected
cells was analyzed using a Student’s T-test (Table S1). The
differential expression of nine genes (AGT, AK5, CNR1, GALR2,
IGFBP7, KISSR1, PLXDC1, PLXNC1 and PROK2) was successfully
validated using quantitative real-time PCR (Figure S2 and Table
S9). The transient transfection and over-expression of USF1
microarray data can be accessed in MIAME compliant format
from NCBI GEO database (GSE17300).
Mexican FCHL Case/Control Gene Expression Microarrays
We collected 70 Mexican FCHL case/control fat biopsies from
umbilical subcutaneous adipose tissue under local anesthesia. Each
participant provided written informed consent. The study design
was approved by the ethics committees of the INCMNSZ and
UCLA. Clinical characteristics are summarized in Table 1.
Differential expression for a subset of these microarrays has been
validated by qRT-PCR previously [22,25]. We have previously
described in detail the procedures for RNA extraction [10,15,25]
and microarray hybridization [22]. After applying the microarray
quality control pipeline, a total of 14,942 probesets passed and
were utilized in analyses. The microarray data can be accessed in
MIAME compliant format from the NCBI Gene Expression
Omnibus (GEO) database (GSE17170).
Microarray Quality Control Pipeline
A rigorous quality control pipeline was developed to prepare the
gene expression microarray data for analysis. First, the CEL files
were imported into R 2.8.0 using the justRMA function of the
Affymetrix library from Bioconductor, which applies background
subtraction and quantile normalization. An alternate CDF file
(U133Plus2msk.cdf.gz) was used to exclude mis-targeted and
nonspecific probes from the microarrays [61], and probesets with
less than 7 remaining probes were also excluded. Probesets with
more than 50% absent calls were excluded, as calculated using the
panp package from Bioconductor. Finally, the ComBat library in
R was used to correct for batch effect [62].
Mexican Microarray Analyses
Only residuals of the clinical traits corrected for significant
covariates, such as age and sex, were used in analyses. There was
minimal relatedness between individuals, but to avoid confounding
due to relatedness all analyses with the Mexican FCHL cases/
controls were corrected for kinship. The lmekin function from the
kinship packageinR was utilized fortheanalysesofdifferential gene
expression. Differential expression of genes based on the FCHL
status was assayed by regressing FCHL status with the covariates
age, sex and kinship on the expression of each gene. Differential
expression of genes based on the additive model for rs3737787
genotypes was assayed by regressing the rare allele counts with the
covariates age, sex, FCHL status and kinship on the expression of
each gene. Significance of the overlap of independent gene lists was
calculated using Fisher’s exact test. We report two-tailed p-values
and fold change of enrichment to demonstrate whether there are
more or less overlapping genes than expected. Functional
enrichment analysis was conducted using the DAVID software
package [63]. The Benjamini-Hochberg (B–H) multiple testing
corrected p-values are reported. Power calculations were conducted
utilizing pwr.r.test function from the pwr package in R.
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(WGCNA)
For the 70 Mexican FCHL case/control fat biopsies, a weighted
gene co-expression network was constructed using the blockwise-
Modules function from the WGCNA package in R [64]. We
utilized residuals of gene expression corrected for age, sex and
kinship in the WGCNA. The blockwiseModules function allows
the entire dataset of 14,942 genes to be utilized in the construction
of the weighted gene co-expression network, by splitting the genes
into sets of less than 2,000 genes [64]. For each set of genes the
pair-wise correlation matrix is computed, and using the power
function the correlations are weighted to a power of b [65]. An
advantage of WGCNA is the fact that the results are highly robust
with respect to the choice of the parameter b [64]. WGCNA is
designed to identify modules of densely interconnected genes by
searching for genes with similar patterns of connectivity with other
genes, which can be summarized as the topological overlap
between genes [65]. Topological overlap is then calculated from
the weighted co-expression matrix, and turned into a dissimilarity
measure (1 - topological overlap) for average linkage hierarchical
clustering. The dynamic tree-cutting algorithm [66] is then used to
identify modules of co-expressed genes. After all blocks have been
processed, a gene is reassigned to another module if it is found to
have higher connectivity to this other module, and modules whose
eigengenes are highly correlated are merged [64]. Genes that are
not assigned to a module are assigned to the grey module. The
maximum block size was set at 2,000 genes; a power (b) was set to
6 as this was found to be optimal (and also happens to be the
default setting); minimum module size was set at 100; the
minimum height for merging modules was set at 0.2; and the
maximum height at which the tree could be cut was set to 1. All
the other parameters were left at default settings.
Causality Testing
To infer causal flow between genetic markers, gene expression
traits and clinical traits, we utilized the single.marker.analysis
function from the Network Edge Orienting (NEO) package in R
[37]. We also utilized residuals of gene expression corrected for age,
sex and kinship in causality testing. There are five different models
for causal flow that are tested in the single.marker.analysis function.
The model of interest for these studies infers a causal flow anchored
bythe SNPrs3737787whichaffectstheexpression ofagene orgene
co-expression module that in turn alters a clinical trait (MRARB).
The fit of this model was assessed using the local structural equation
model (SEM) based, edge orienting, next best single marker
(LEO.NB.SingleMarker) score, which is the log10 probability of this
model divided by the log10 probability of the next best fitting
alternative model [37]. We chose to use the same threshold as
utilized by Presson et al., where the LEO.NB.SingleMarker score was
required to be positive and at least twice as probable as the next best
alternative model, a LEO.NB.SingleMarker score of 0.3<log10(2)
[31]. Thus any LEO.NB.SingleMarker score greater than or equal to
0.3 was considered sufficient to infer causal flow.
Mexican FCHL Families
A total of 872 individuals from 74 Mexican FCHL families were
collected at Instituto Nacional de Ciencias Medicas y Nutricion,
Salvador Zubiran, as described previously [22,25]. The 90
th age-
sex specific Mexican population percentiles for TGs and TC were
used to determine the affection status, as described previously
[22,25]. Each participant provided written informed consent. The
study design was approved by the ethics committees of the
INCMNSZ and UCLA.
Genotyping
The rs3737787, rs174547 and rs102275 SNPs were genotyped
using the pyrosequencing technique (Biotage). Primers for PCR
were designed using the Primer3 software [67], and labeled
detection primers using SNP Primer Design software (Biotage).
Sequencing was performed using an ABI 377XL automated DNA
sequencer (Applied Biosystems). All SNPs had at least 90%
genotype call rate in each study sample, and when necessary
individuals were sequenced to achieve at least a 90% genotype call
rate for each SNP.
Genetic Association Testing
All genetic association testing was conducted using qualitative
phenotypes, where the continuous FCHL related phenotypes are
dichotomized by the 90
th age-sex specific percentiles of TGs and
TC. Association for the Mexican FCHL fat biopsy case/control
study sample was calculated by regressing genotypes in an additive
model to the dichotomized trait of interest using logistic regression
with the glm function in R. We utilized the Family Based
Association Testing (FBAT) software package to test for associa-
tion in the Mexican FCHL families [68]. Because the FADS1-2-3
locus resides in a linked region, the -e option of FBAT was used.
This option utilizes a null model of no association in the presence
of linkage. FBAT implements a generalization of the transmission
disequilibrium test (TDT) [69] in the extended pedigrees. Thus,
FBAT is not sensitive to population stratification or admixture
[68–70]. The FBAT –e option also corrects for cryptic relatedness.
Due to these features FBAT -e provides a robust test for
association in these extended Mexican families.
Supporting Information
Figure S1 Western blot demonstrating HEK293T endogenous
USF1 expression and USF1 over-expression at the protein level.
Protein collected from HEK293T cells transfected with USF1 is
labeled USF1 overexpression, protein collected from HEK293T
cells transfected with an empty vector is labeled Empty Vector, and
protein collected from HEK293T cells which were not tranfected is
labeled HEK293T. Protein amounts were quantitated using BCA
assayand10 mgofproteinwasloadedforeachlane.(A)Probedwith
Anti-HisG-HRP antibody which should detect only the over
expressed USF1 protein with a polyhistidine tag. (B) Probed with
Anti-USF1 antibody, which will detect over expressed as well as
endogenous USF1 and demonstrates the relative amount of over-
expression of USF1. This also demonstrates that the HEK293T cell
line does express USF1 protein at a detectable level by western blot.
Found at: doi:10.1371/journal.pgen.1000642.s001 (1.00 MB EPS)
Figure S2 qRT-PCR validation of genes identified as differen-
tially expressed due to USF1 over-expression on microarrays. The
validation genes were: AGT=angeotensin, AK5=adenylate kinase
5, CNR1=canaboid receptor 1, GALR2=galanin receptor 2,
IGFBP7=insulin-like growth factor binding protein 7, KISS1R=-
KISS1 receptor, PLXDC1=plexin domain containing 1,
PLXNC1=plexin C1, and PROK2=prokineticin 2. The endoge-
nous housekeeping controls were: B2M=beta-2-microglobulin,
and HPRT=hypoxanthine phosphoribosyltransferase. Student’s t-
test p-values were calculated between USF1 over-expression and
Empty Vector control, and a single asterisk (*) indicates a p-
value#0.05, a double asterisk (**) indicates a p-value#0.005, and
a triple asterisk (***) indicates a p-value#0.0005.
Found at: doi:10.1371/journal.pgen.1000642.s002 (0.99 MB EPS)
Table S1 Genes differentially expressed by USF1 over-expres-
sion in HEK293T cells (p-value#0.05).
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Table S2 Genes correlated to FCHL-associated rs3737787
genotypes (additive model) in Mexican FCHL case/control fat
biopsies (p-value#0.05).
Found at: doi:10.1371/journal.pgen.1000642.s004 (0.64 MB PDF)
Table S3 Genes differentially expressed between FCHL cases
and normolipidemic controls in Mexican FCHL case/control fat
biopsies (p-value#0.05).
Found at: doi:10.1371/journal.pgen.1000642.s005 (1.42 MB PDF)
Table S4 WGCNA module membership for all probes from the
Mexican FCHL case/control fat biopsies.
Found at: doi:10.1371/journal.pgen.1000642.s006 (11.40 MB
ZIP)
Table S5 Functionally enriched annotation terms for the set of
genes comprising each co-expression module (Benjamini-Hoch-
berg corrected p-value#0.05).
Found at: doi:10.1371/journal.pgen.1000642.s007 (0.11 MB PDF)
Table S6 Trait variance explained by WGCNA co-expression
module eigengenes (Adjusted R
2).
Found at: doi:10.1371/journal.pgen.1000642.s008 (0.02 MB PDF)
Table S7 Causality testing results for URFA module genes
terminating in FCHL, TC, TG, and ApoB.
Found at: doi:10.1371/journal.pgen.1000642.s009 (0.38 MB PDF)
Table S8 Previous association evidence with lipid or atherogenic
traits for genes causally linked to FCHL from the URFA module.
Found at: doi:10.1371/journal.pgen.1000642.s010 (0.07 MB PDF)
Table S9 qRT-PCR primers for validation of genes identified as
differentially expressed due to USF1 over-expression on micro-
arrays.
Found at: doi:10.1371/journal.pgen.1000642.s011 (0.01 MB PDF)
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